FGEN Fibrogen Inc

Price (delayed)

$11.62

Market cap

$1.08B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.04

Enterprise value

$995.15M

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue ...

Highlights
FGEN's gross profit is up by 36% year-on-year and by 10% since the previous quarter
The company's revenue rose by 35% YoY and by 10% QoQ
The company's debt has surged by 180% YoY but it fell by 2.8% QoQ
The net income has dropped by 54% year-on-year but it is up by 2.9% since the previous quarter
FGEN's equity has dropped by 57% year-on-year and by 24% since the previous quarter
The quick ratio has contracted by 47% YoY

Key stats

What are the main financial stats of FGEN
Market
Shares outstanding
93.3M
Market cap
$1.08B
Enterprise value
$995.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.84
Price to sales (P/S)
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.86
Earnings
Revenue
$257.71M
EBIT
-$280.47M
EBITDA
-$268.42M
Free cash flow
-$52.03M
Per share
EPS
-$3.04
Free cash flow per share
-$0.56
Book value per share
$1.7
Revenue per share
$2.77
TBVPS
$8.02
Balance sheet
Total assets
$745.93M
Total liabilities
$567.92M
Debt
$96.93M
Equity
$158.05M
Working capital
$269.04M
Liquidity
Debt to equity
0.61
Current ratio
2.05
Quick ratio
1.85
Net debt/EBITDA
0.33
Margins
EBITDA margin
-104.2%
Gross margin
94.7%
Net margin
-109.2%
Operating margin
-109.1%
Efficiency
Return on assets
-35.4%
Return on equity
-118.1%
Return on invested capital
-67%
Return on capital employed
-57.2%
Return on sales
-108.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FGEN stock price

How has the Fibrogen stock price performed over time
Intraday
-0.77%
1 week
17.02%
1 month
36.38%
1 year
-60.06%
YTD
-17.59%
QTD
-3.33%

Financial performance

How have Fibrogen's revenue and profit performed over time
Revenue
$257.71M
Gross profit
$244M
Operating income
-$281.1M
Net income
-$281.47M
Gross margin
94.7%
Net margin
-109.2%
FGEN's operating income has dropped by 55% year-on-year but it is up by 2.6% since the previous quarter
The net income has dropped by 54% year-on-year but it is up by 2.9% since the previous quarter
FGEN's gross profit is up by 36% year-on-year and by 10% since the previous quarter
The company's revenue rose by 35% YoY and by 10% QoQ

Growth

What is Fibrogen's growth rate over time

Valuation

What is Fibrogen stock price valuation
P/E
N/A
P/B
6.84
P/S
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.86
The company's EPS has shrunk by 50% YoY but it rose by 3.2% QoQ
FGEN's equity has dropped by 57% year-on-year and by 24% since the previous quarter
The stock's price to book (P/B) is 12% less than its 5-year quarterly average of 7.8 but 7% more than its last 4 quarters average of 6.4
The stock's price to sales (P/S) is 79% less than its 5-year quarterly average of 19.6 and 39% less than its last 4 quarters average of 6.9
The company's revenue rose by 35% YoY and by 10% QoQ

Efficiency

How efficient is Fibrogen business performance
FGEN's return on equity has dropped by 165% year-on-year and by 19% since the previous quarter
FGEN's return on assets has dropped by 57% year-on-year
FGEN's return on invested capital is up by 26% year-on-year and by 13% since the previous quarter
The company's return on sales fell by 15% YoY but it rose by 11% QoQ

Dividends

What is FGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FGEN.

Financial health

How did Fibrogen financials performed over time
FGEN's total assets is 31% greater than its total liabilities
The quick ratio has contracted by 47% YoY
FGEN's current ratio is down by 45% year-on-year and by 2.4% since the previous quarter
The company's debt is 39% lower than its equity
The company's debt has surged by 180% YoY but it fell by 2.8% QoQ
FGEN's equity has dropped by 57% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.